The British company expects to report "substantial growth" in its food intolerance testing line for full-year 2009, and sales of its microarray-based Genarrayt platform are expected to rise 44 percent to £1.04 million from £72,000 in 2008.
So far this year, Rosetta has found commercialization partners for the diagnostics in the Middle East, Canada, the US, and India.
The arrangement gives Super Religare the rights to distribute the tests in India, Saudi Arabia, Qatar, and the United Arab Emirates.
SRL will distribute Rosetta’ Genomics’ microRNA cancer tests in India, Saudi Arabia, Qatar, and in the UAE.
The service is SRL's first array-based test and could foreshadow the adoption of more array-based diagnostics by the Indian testing giant.
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.